Morepen Labs Q1 FY27: Revenue up 34%, PAT jumps over 5x YoY

Revenue Growth 20pctPat Growth 25pctRelated Party TransactionsResults View source PDF Explain this filing

MOREPENLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+20.5%Reaction day

₹57.40

prior close

₹56.24

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+20.1% vs market

Pharmaceuticals peers, median of 165sector-0.0%+20.6% vs sector

On the reaction day the stock moved 20.1 pts more than Nifty Microcap 250 and 20.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+15.4

10m

+17.6

15m

+21.3

30m

+23.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+20.5+0.4+20.1-0.0+20.6

Next day

+33.6+1.7+31.9+0.0+33.6

+38.6+2.1+36.5+0.2+38.4

+39.4+2.1+37.3+0.4+39.0

+39.5+2.1+37.5+0.6+38.9

+33.8+1.9+31.9+0.8+33.0

+41.6+2.4+39.2+0.4+41.3

15d

+63.4+3.0+60.4+0.5+63.0

+97.9+3.7+94.2+1.0+96.9

+136.4+1.6+134.9+2.0+134.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Morepen Labs Q1 FY27 consolidated revenue grew 34% YoY to Rs 57,012.81 lakhs from Rs 42,523.88 lakhs. Net profit after minority interest jumped over 5x to Rs 5,639.94 lakhs from Rs 1,074.83 lakhs. EPS rose to Rs 1.03 from Rs 0.20. Board fixed Sept 19, 2026 as record date for final dividend, approved hiving off Medical Devices business into Morepen Medipath Ltd as a material related party transaction on slump sale basis, and re-appointment of CMD Sushil Suri for 3 more years from Oct 20, 2026.

Likely market impact

Strong topline and profit growth signal improved operating efficiency. Dividend record date, hive-off plan, and CMD continuity add positive sentiment.